Michael H. Föhlings
… is Managing Director (CFO) of TRON.
Michael joined TRON in 2011 as Managing Director to build its financial and administrative structure from scratch, with an outstanding track record for establishing a number of financial and administrative organizations from the ground up internationally.
During his 30 years career in auditing, glass, steel and polymer industries, Michael has held diverse senior financial and general management functions as CFO and MD in British, Anglo-Dutch and Swiss multinational companies. Concomitantly he was also a member of executive boards in Germany, Italy, Spain, the United States and China. As a practitioner in the financial management of international multi-site groups operating in manufacturing environments, Michael gained practical experience in restructuring and repositioning companies in Germany, Spain and the US.
Michael studied business administration, business and labour law and real estate management at Westfälische Wilhelms-University Münster, EBS European Business School, Schloss Reichartshausen and IMD, Lausanne, Switzerland. He holds Diplomas in Business Administration and Real Estate Management.
Andrée Rothermel, PhD
… is Managing Director (CSO) of TRON.
Andrée has many years of experience in drug and biomarker development and professional project management. As a molecular biologist, he has been instrumental in establishing academic and industrial research institutions. For example, he helped establish the Department of Molecular Biological-Biochemical Processing Technology at the Centre for Biotechnology and Biomedicine at the University of Leipzig, and founded the “Integrative Nano-Bioengineering” section of the German Society for Biomedical Engineering. In Mainz, he was integral in building up TRON in the early years, and as the director of the Biomarker Development Center (2014-2020) he has overseen the development of innovative platforms for immunodiagnostics. Since November 1, 2020, Andrée has been Managing Director with a remit to guide TRON’s scientific strategy.
Andrée received his doctorate at the Technical University of Darmstadt and his habilitation at the University of Leipzig in 2008, where he also received teaching authorization. He was central in the creation of the Ci3 leading-edge cluster and, after the funding phase, he continued leadership as cluster manager and as managing director in 2016-2018. In addition to his activities at TRON and Ci3, Andrée has also headed the Serodiscovery functional unit of BioNTech Diagnostics GmbH since 2010.
Ugur Sahin, M.D.
… is Co-Founder and Shareholder of TRON.
Ugur is a doctor of medicine, immunologist and cancer researcher. His key focus is translating groundbreaking novel scientific ideas into medical innovations that help individual patients, an interest that was originally prompted by his experiences as a trained physician. His made key contributions in various fields of cancer immunotherapy, covering the discovery of tumor-associated antigens, development of novel monoclonal antibodies for the treatment of solid cancers and various classes of RNA-based immunotherapies. Together with his team he has pioneered the concept of individualized cancer immunotherapies and in particular the development of mRNA-based vaccines that are tailored to each patient´s cancer mutation profile. Ugur is a Professor at the University Medical Center of Johannes Gutenberg University Mainz, co-founder and CEO of BioNTech and co-founder und shareholder of TRON. He was TRON´s scientific managing director from 2010 until September 2019. Ugur supports the research and development at TRON as a close scientific advisor and supervisor for PhD students.